BMC Nephrology | |
Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection | |
Research Article | |
L. Jiang1  T. Pedersen2  A. Cass3  N. Staplin4  W. G. Herrington4  C. Reith4  J. Armitage4  W. Stevens4  M. J. Landray4  M. Mafham4  C. Baigent5  R. Haynes5  J. Emberson5  J. C. Craig6  | |
[1] Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China;Centre of Preventive Medicine, Oslo University Hospital, Oslo, Norway;Faculty of Medicine, University of Oslo, Oslo, Norway;Menzies School of Health Research, Charles Darwin University, Darwin, Australia;Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK;Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK;Medical Research Council-Population Health Research Unit (MRC-PHRU), NDPH, University of Oxford, Oxford, UK;Sydney School of Public Health, University of Sydney, Sydney, Australia; | |
关键词: Chronic Kidney Disease; Simvastatin; Statin Therapy; Ezetimibe; Albumin Creatinine Ratio; | |
DOI : 10.1186/s12882-017-0545-2 | |
received in 2016-08-24, accepted in 2017-04-01, 发布年份 2017 | |
来源: Springer | |
【 摘 要 】
BackgroundReducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of major atherosclerotic events among patients with chronic kidney disease (CKD), with no evidence of an excess risk of cancer or death from any non-vascular cause. However, non-randomized data have suggested that statin therapy may have effects (both adverse and beneficial) on particular non-vascular conditions that do not cause death.MethodsThe Study of Heart and Renal Protection (SHARP) randomized patients with CKD to simvastatin 20 mg plus ezetimibe 10 mg (simvastatin/ezetimibe) daily versus matching placebo. Participants were followed up at least 6 monthly and all post-randomization serious adverse events (SAEs) were recorded. This supplementary analysis reports the effects of treatment on non-vascular SAEs, overall, by system of disease, by baseline characteristics, and by duration of follow-up.ResultsDuring a median of 4.9 years follow-up, similar numbers of participants in the two groups experienced at least one non-vascular SAE (3551 [76.4%] simvastatin/ezetimibe vs 3537 [76.6%] placebo; risk ratio [RR] 0.99, 95% confidence interval [CI] 0.95–1.04). There was no good evidence of any significant effect of simvastatin/ezetimibe on SAEs attributed to any particular nonvascular disease system (of 43 comparisons, only 3 yielded an uncorrected p value < 0.05, of which the smallest was p = 0.02). The relative risk of any nonvascular SAE did not vary significantly among particular prognostic subgroups or by duration of follow-up.ConclusionsIn the SHARP trial, allocation to simvastatin/ezetimibe combination therapy was not associated with any significant non-vascular hazard.Trials registrationSHARP was retrospectively registered after the first participant was enrolled in 2003 at ISRCTN (ISRCTN54137607 on 31 January 2005: http://www.isrctn.com/ISRCTN54137607) and ClinicalTrials.gov (NCT00125593 on 29 July 2005: https://clinicaltrials.gov/ct2/show/NCT00125593).
【 授权许可】
CC BY
© The Author(s). 2017
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311109722708ZK.pdf | 1030KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]